TaiGen Biopharmaceuticals Holdings (ROCO:4157) ROCE %: 86.42% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4157 TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
59 GF Score
Price NT$8.87
GF Value NT$34.16
Valuation Significantly Undervalued
View Full Analysis

What is TaiGen Biopharmaceuticals Holdings ROCE %?

TaiGen Biopharmaceuticals Holdings ROCO:4157 +3.14% 59 ROCE % is 86.42% as of Dec. 2025. GuruFocus rates ROCO:4157 with a GF Score™ of 59/100 and a GF Value™ of NT$34.16 (Significantly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TaiGen Biopharmaceuticals Holdings's annualized ROCE % for the quarter that ended in Dec. 2025 was 86.42%.

TaiGen Biopharmaceuticals Holdings  (ROCO:4157) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TaiGen Biopharmaceuticals Holdings ROCE % Related Terms

TaiGen Biopharmaceuticals Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for TaiGen Biopharmaceuticals Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiGen Biopharmaceuticals Holdings ROCE % Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.32 -19.92 13.28 -2.72 5.34

TaiGen Biopharmaceuticals Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.45 -8.06 -46.60 -5.60 86.42
ROCO:4157
59GF Score
TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiGen Biopharmaceuticals Holdings ROCE % Calculation

TaiGen Biopharmaceuticals Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=59.106/( ( (1174.282 - 46.084) + (1167.254 - 83.105) )/ 2 )
=59.106/( (1128.198+1084.149)/ 2 )
=59.106/1106.1735
=5.34 %

TaiGen Biopharmaceuticals Holdings's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=868.52/( ( (1013.382 - 87.52) + (1167.254 - 83.105) )/ 2 )
=868.52/( ( 925.862 + 1084.149 )/ 2 )
=868.52/1005.0055
=86.42 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 86.42% mean?
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a ROCE % of 86.42% as of Dec. 2025.
Is TaiGen Biopharmaceuticals Holdings' ROCE % too high?
TaiGen Biopharmaceuticals Holdings' current ROCE % is 86.42%. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' ROCE % compare to VRTX and REGN?
TaiGen Biopharmaceuticals Holdings' ROCE % of 86.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. TaiGen Biopharmaceuticals Holdings's current ROCE % is 86.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.16, compared to a current price of NT$8.87 — trading 74% below its estimated fair value. The current ROCE % is 86.42%. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current ROCE % is 86.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?

Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued. The current stock price of NT$8.87 is trading 74% below its estimated GF Value™ of NT$34.16. GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.

Key valuation signals for ROCO:4157:

  • ROCE %: 86.42%
  • GF Value™: NT$34.16 vs. price of NT$8.87 (74% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiGen Biopharmaceuticals Holdings Business Description

Address No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score

Get the complete analysis for ROCO:4157

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$8.87
Price
NT$34.16
GF Value